Head & Neck Cancer

TROG HeadSTART results puzzling

20/05/2010 | Adding the hypoxic cytotoxin tirapazamine to chemoradiotherapy does not improve overall survival in unselected patients with advanced head and neack cancer, research shows.


Drug disappoints in recurrent glioblastoma

05/02/2010 | Hopes for treating recurrent glioblastoma with enzastaurin - a targeted anti-angiogenic - have been dashed by disappointing phase III study results.


Challenging behaviour under-recognised

20/11/2009 | Challenging behaviour in brain tumour patients is an under-recognised clinical problem that impacts on both clinicians and carers, a study finds.


New Australian glioma guidelines

20/11/2009 | The classic "brain tumour headache" - there on waking, fading shortly after rising and lasting longer over time - is not a reliable pointer for diagnosis, Australian experts say.


Adding chemotherapy improves survival in head and neck cancer

30/10/2009 | Giving chemotherapy at the same time as radiotherapy to patients with locally advanced head and neck cancer who have not had surgery doubles their event free survival, results from the UKHAN1 trial show.


Oesophageal cancer on the increase

23/09/2009 | The incidence of oesophageal adenocarcinoma is increasing and more support to target risk factors such as smoking and diet is needed to improve survival, Australian researchers conclude.


Swallowing outcomes identified

28/08/2009 | Australian researchers have identified the factors most likely to influence swallowing ability after chemoradiotherapy.


Post-treatment pain associated with survival rate

18/08/2009 | Patients with head and neck cancer who experience higher levels of post-treatment pain have a lower chance of survival, a report finds.


Bevacizumab improves PFS in for glioblastoma multiforme

04/06/2009 | The addition of bevacizumab to temozolomide and radiation therapy, followed by combination treatment with bevacizumab, temozolomide, and irinotecan, improves progression-free survival at just over one year in almost two-thirds of patients with newly diagnosed glioblastoma multiforme, a small phase II study shows.


Capecitabine travel warning

29/05/2009 | A 62-year-old Singapore man with metastatic nasopharyngeal carcinoma was temporarily denied entry into the U.S. because the capecitabine he was taking made his fingerprints disappear, according to a letter published in the Annals of Oncology.


More Head & Neck Cancer news

Most viewed articles this week

Recent comments

Related sites